STRO News and Press, Sutro Biopharma Inc.

2026-05-28 05:15:03 ET Lukas Shumway from Barclays issued a price target of $56.00 for STRO on 2026-05-28 07:36:00. The adjusted price target was set to $56.00. At the time of the announcement, STRO was trading at $29.69. The overall price target consensus is at $50.75 w...

A look at the top 10 most actives in the United States HCW Biologics Inc. (HCWB) rose 300.3% to $1.3489 on volume of 171,246,051 shares EZGO Technologies Ltd. (EZGO) fell 32.6% to $0.018 on volume of 132,645,341 shares Direxion Daily Semiconductor Bear 3X (SOXS) rose 11.5% to $9.225 on volu...

2026-05-15 07:29:42 ET More on small cap IJR Vs. SPY: The Small-Large Valuation Gap Has Closed The Stagflation Narrative: What Doomers Get Wrong (Part 2) Brace For Stage Two Of The Global Energy Crisis Deregulation could ease inflation pressures, Fed’s...

2026-05-15 07:15:06 ET H.C. Wainwright analyst issues BUY recommendation for STRO on May 15, 2026 10:16AM ET. The previous analyst recommendation was Buy. STRO was trading at $38.42 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2026-05-14 16:38:51 ET More on Sutro Biopharma Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell Sutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - Slideshow Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 ...

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 progr...

2026-05-06 09:00:00 ET Showcase Intro In April, we welcomed 31 new analysts who published their first-ever article on Seeking Alpha. In this article, our editors highlight some of the best ideas from these new analysts and introduce them. The first five introductions are spotlig...

2026-04-30 23:22:26 ET Editor's note: Seeking Alpha is proud to welcome Bern Lake Investor as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Pr...

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targ...

2026-03-23 16:14:00 ET More on Sutro Biopharma Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 Sutro Biopharma, Inc. (STRO) Presents at 16th Annual World ADC London Summit - Slideshow Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J...